Retraction: Effect of short-term thiamine supplementation on oxidative stress, inflammation, exercise capacity and prognosis in chronic heart failure: a randomized clinical trial Retraction: Thiamine in the treatment of CHF.
Main Article Content
Keywords
Thiamine; Chronic heart failure; Oxidative stress; Inflammation; Exercise capacity; Rehospitalization.
Abstract
THIS ARTICLE HAS BEEN RETRACTED
Background and aim: Thiamine has known antioxidative and anti-inflammatory effects. However, the effectiveness of thiamine supplementation and clinical outcome in chronic heart failure (CHF) are unclear. Therefore, this study focuses on evaluating the effect of short-term thiamine supplementation on oxidative stress, inflammation, exercise capacity, and predicts the ability of rehospitalization within 30-day in patients with CHF.
Methods: Sixty hospitalized patients with CHF were randomly divided into two groups. Both groups received conventional anti-heart failure treatment, but the thiamine group (n=30) received thiamine (100 mg/day) by intramuscular injection for 1 week, while the control group (n=30) did not do it. Serum thiamine, malondialdehyde (MDA), superoxide dismutase (SOD), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), pro-B-type natriuretic peptide (pro-BNP) levels and 6-minute walking distance (6MWD) were detected in the two groups before and after the treatment, and all the participants were followed-up for 30-day after discharge.
Results: After 1 week of treatment, serum thiamine levels were significantly decreased in control group compared with baseline (p＜0.05), and the SOD levels and 6MWD in the thiamine group were significantly increased compared with the control group (p＜0.05). Serum thiamine levels in the thiamine group were independent determinants of serum SOD levels (standardized coefficient=0.4, p=0.022) and 6MWD (standardized coefficient=0.518, p=0.004) after thiamine supplementation. Serum thiamine levels before discharge (hazard ratio [HR], 0.957, 95% confidence interval [CI], 0.924 to 0.992; p=0.016) was independently related to the rehospitalization within 30-day.
Conclusions: In conclusion, short-term thiamine supplementation could improve oxidative stress and exercise capacity, and serum thiamine levels before discharge was an independent predictor of rehospitalization within 30-day. Meanwhile, furosemide could reduce serum thiamine levels in patients with CHF.
References
2. Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020; 27: 494-510.
3. Eshak ES, Arafa AE. Thiamine deficiency and cardiovascular disorders. Nutr Metab Cardiovasc Dis. 2018; 28: 965-72.
4. Goel A, Kattoor AJ, Mehta JL. Thiamin therapy for chronic heart failure: is there any future for this vitamin? Am J Clin Nutr. 2019; 110: 1270-71.
5. Katta N, Balla S, Alpert MA. Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review. Am J Med. 2016; 129: 753 e7-53 e11.
6. Yue QY BB, Lindström B, Nyquist O. No difference in blood thiamine diphosphate levels between Swedish Caucasian patients with congestive heart failure treated with furosemide and patients without heart failure. J Intern Med. 1997; 242: 491-95.
7. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006; 47: 354-61.
8. Gioda CR, de Oliveira Barreto T, Primola-Gomes TN, et al. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am J Physiol Heart Circ Physiol. 2010; 298: H2039-45.
9. Okai Y H-OK, Sato EF, Konaka R, Inoue M. Potent radical-scavenging activities of thiamin and thiamin diphosphate. J Clin Biochem Nutr 2007; 40: 42-8.
10. Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovascular Drugs and Therapy. 2017; 31: 593-608.
11. Karuppagounder SS, Shi Q, Xu H, Gibson G E. Changes in inflammatory processes associated with selective vulnerability following mild impairment of oxidative metabolism. Neurobiol Dis. 2007; 26: 353-62.
12. Liu D, Ke Z, Luo J. Thiamine Deficiency and Neurodegeneration: the Interplay Among Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy. Mol Neurobiol. 2017; 54: 5440-48.
13. Abdou E, Hazell AS. Thiamine deficiency: an update of pathophysiologic mechanisms and future therapeutic considerations. Neurochem Res. 2015; 40: 353-61.
14. Lynch PL, Young IS. Determination of thiamine by high-performance liquid. J Chromatogr A. 2000; 881: 267-84.
15. Manzetti S, Zhang J, van der Spoel D. Thiamin function, metabolism, uptake, and transport. Biochemistry. 2014; 53: 821-35.
16. Dey S, DeMazumder D, Sidor A, Brian Foster D, O’Rourke B. Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure. Circ Res. 2018; 123: 356-71.
17. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002; 40: 477-84.
18. Zhao Y, Pan X, Zhao J, Wang Y, Peng Y, Zhong C. Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency. J Neurochem. 2009; 111: 537-46.
19. Alam SS, Riaz S, Waheed Akhtar M. Effect of high dose thiamine therapy on activity and molecular aspects of transketolase in Type 2 diabetic patients. African Journal of Biotechnology. 2011; 10:17305-16.
20. Riyapa D, Rinchai D, Muangsombut V, et al. Transketolase and vitamin B1 influence on ROS-dependent neutrophil extracellular traps (NETs) formation. PLoS One. 2019; 14: 1-17.
21. Ahmed LA, Hassan OF, Galal O, Mansour DF, El-Khatib A. Beneficial effects of benfotiamine, a NADPH oxidase inhibitor, in isoproterenol-induced myocardial infarction in rats. PLoS One. 2020; 15:1-17.
22. Sarandol E, Tas S, Serdar Z, Dirican M. Effects of thiamine treatment on oxidative stress in experimental diabetes. Bratisl Lek Listy. 2020; 121: 235-41.
23. Radonjic T, Rankovic M, Ravic M, et al. The Effects of Thiamine Hydrochloride on Cardiac Function, Redox Status and Morphometric Alterations in Doxorubicin-Treated Rats. Cardiovasc Toxicol. 2020; 20: 111-20.
24. González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramírez-Ramírez V, Ramos-Zavala MG. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr. 2011; 50: 145-9.
25. Amirani E, Aghadavod E, Shafabakhsh R, et al. Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020: 1-6.
26. Smithline HA, Donnino M, Blank FSJ, et al. Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial. BMC Complementary and Alternative Medicine. 2019;19:1-11.
27. Keith M, Quach S, Ahmed M, et al. Thiamin supplementation does not improve left ventricular ejection fraction in ambulatory heart failure patients: a randomized controlled trial. Am J Clin Nutr. 2019; 110: 1287-95.
28. Yamada Y KY, Akaoka M, Watanabe M, et al. Thiamine treatment preserves cardiac function against ischemia injury via maintaining mitochondrial size and ATP levels. J Appl Physiol 2021; 130: 26-35.
29. Li X, Luan H, Zhang H, et al. Associations between early thiamine administration and clinical outcomes in critically ill patients with acute kidney injury. The British journal of nutrition. 2021: 1-9.
30. Ao M YK, Ohta J, Abe Y, et al. Possible involvement of thiamine insufficiency in heart failure in the institutionalized elderly. J Clin Biochem Nutr. 2019; 64: 239-42.
31. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: A pilot study. Am J Med. 1991; 91: 151-55.
32. Whitfield KC, Bourassa MW, Adamolekun B, et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018; 1430: 3-43.
33. Zeng L, Wu X, Liu L, Xu L, Kuang H, Xu C. Production of a monoclonal antibody for the detection of vitamin B1 and its use in an indirect enzyme-linked immunosorbent assay and immunochromatographic strip. J Mater Chem B. 2020; 8: 1935-43.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
